When You Start Hormone Therapy May Matter as Much as Whether You Start
A large 2026 analysis in *JAMA Internal Medicine* has given midlife women a clearer question to bring into the exam room: not only *should I consider hormone therapy?* but *when does the window open, and when does it close?
The study followed more than 2,700 women in the Study of Women’s Health Across the Nation (SWAN) who had hot flashes or night sweats and no prior heart disease. Researchers used twenty years of data and a method designed to mimic a clinical trial. Women who began menopausal hormone therapy during perimenopause or early postmenopause had about a “22% lower” rate of later cardiovascular events than similar women who did not start therapy.
The association was stronger when treatment began **within ten years of the final menstrual period**, about a “27%” lower risk. Starting more than a decade after menopause showed **no benefit**. The signal was most pronounced among Black women in the cohort.
That last point matters. Vasomotor symptoms are often more frequent and last longer in Black women, and they have been under-represented in the studies that still shape public fear of hormone therapy.
What this does "not" mean
The authors were explicit: these findings should **not** be used to prescribe hormone therapy solely to prevent heart disease.
This was observational research, not a randomized trial. Women who choose hormone therapy often differ from those who do not, in access to care, income, race and ethnicity, and day-to-day health habits. Some of the apparent heart benefit may reflect those differences. Formulations in the dataset were mixed. Modern transdermal estradiol and micronized progesterone were not cleanly isolated from older oral regimens.
In short: timing looks important. Causation is not proven. Individual risk still governs the decision.
Why the “timing hypothesis” keeps returning
The Women’s Health Initiative enrolled many women who were older and further from menopause than the patients who now walk into a hormone-optimization practice. That trial answered a different question than the one most symptomatic women in their late forties and early fifties are asking.
The SWAN analysis sits closer to real clinic life: midlife, bothersome hot flashes or night sweats, no established heart disease, and a decision about whether to treat the transition rather than wait until symptoms have already worn the vascular system down.
Hot flashes are not only a quality-of-life problem. They track with later cardiovascular risk. Treating the symptom and supporting the vessel at the same stage of life is the idea this paper is circling, without overclaiming it.
A more useful conversation than “HRT: yes or no”
If you are in perimenopause or the first years after menopause, a better set of questions is:
– How close am I to my last period?
– How disruptive are vasomotor symptoms, sleep, mood, and sexual function?
– What is my personal risk for clot, stroke, breast cancer, and heart disease?
– Which route and dose (transdermal estradiol, oral estrogen, progesterone type) fit that risk profile?
– What else is aging the system at the same time: insulin resistance, lipids, blood pressure, training, alcohol, sleep?
Hormone therapy is one tool. It is not a longevity protocol by itself, and it is not appropriate for every woman, every year after menopause.
The clinic standard we use
Care should be timed, dosed, and monitored, not branded as anti-aging. That means a full history, symptom mapping, appropriate labs (not a shopping-cart hormone panel), and a plan that can be stopped or changed when the risk–benefit math changes.
New data like this week’s SWAN paper refine the conversation. They do not replace it.
*This article is for education. It is not medical advice and does not establish a patient relationship. Decisions about menopausal hormone therapy belong with you and a clinician who knows your history.*
BOOK A CONSULTATION if you want that conversation applied to your history and labs.
